HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Kazuyuki Shimada Selected Research

azelnidipine

3/2013Study of sustained blood pressure-lowering effect of azelnidipine guided by self-measured morning and evening home blood pressure: subgroup analysis of the At-HOME study.
3/2013Inhibitory effects of azelnidipine tablets on morning hypertension.
4/2011Urinary albumin excretion during angiotensin II receptor blockade: comparison of combination treatment with a diuretic or a calcium-channel blocker.
5/2010Effects of combination olmesartan medoxomil plus azelnidipine versus monotherapy with either agent on 24-hour ambulatory blood pressure and pulse rate in Japanese patients with essential hypertension: additional results from the REZALT study.
1/2010A New Baroreceptor Sensitivity-Restoring Ca-Channel Blocker Diminishes Age-Related Morning Blood Pressure Increase in Hypertensive Patients: Open-Label Monitoring of Azelnidipine Treatment for Hypertension in the Early Morning (At-HOME) Study.
12/2009A randomized, double-blind, four-arm parallel-group study of the efficacy and safety of azelnidipine and olmesartan medoxomil combination therapy compared with each monotherapy in Japanese patients with essential hypertension: the REZALT study.
6/2007Effects of new calcium channel blocker, azelnidipine, and amlodipine on baroreflex sensitivity and ambulatory blood pressure.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Kazuyuki Shimada Research Topics

Disease

57Hypertension (High Blood Pressure)
01/2020 - 01/2002
30Stroke (Strokes)
01/2020 - 01/2002
26Neoplasms (Cancer)
09/2022 - 04/2003
23Cardiovascular Diseases (Cardiovascular Disease)
12/2022 - 10/2002
20Coronary Artery Disease (Coronary Atherosclerosis)
07/2012 - 03/2002
19Lymphoma (Lymphomas)
12/2021 - 02/2004
17Myocardial Infarction
01/2019 - 01/2002
13Atherosclerosis
01/2014 - 03/2002
12B-Cell Lymphoma (Lymphoma, B Cell)
01/2022 - 02/2004
11Inflammation (Inflammations)
07/2012 - 03/2002
10Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse)
10/2021 - 04/2008
10Diabetes Mellitus
04/2018 - 04/2007
8Heart Failure
09/2022 - 05/2003
8Essential Hypertension
05/2015 - 05/2002
7Chronic Renal Insufficiency
12/2015 - 04/2007
6Left Ventricular Hypertrophy (Ventricular Hypertrophy, Left)
12/2022 - 10/2004
6Hemorrhage
02/2020 - 03/2006
6Hypoxia (Hypoxemia)
02/2017 - 11/2005
6Obesity
06/2012 - 07/2007
6Cerebrovascular Disorders (Cerebrovascular Occlusion)
12/2011 - 07/2002
6Cerebral Infarction
11/2011 - 10/2003
5Isolated Systolic Hypertension
01/2017 - 09/2004
5Ischemic Stroke
01/2016 - 02/2004
5Masked Hypertension
03/2015 - 04/2007
5Cardiomegaly (Heart Hypertrophy)
06/2012 - 12/2002
5Hypercholesterolemia
01/2012 - 10/2004
5Atherosclerotic Plaque (Atheroma)
10/2004 - 03/2002
4Disease Progression
08/2020 - 10/2005
4Dyslipidemias (Dyslipidemia)
01/2019 - 03/2010
4Sleep Apnea Syndromes (Sleep Apnea)
10/2012 - 09/2006
4Unstable Angina
01/2011 - 04/2002
4Pulmonary Arterial Hypertension
09/2007 - 10/2006
3Lymphoproliferative Disorders (Lymphoproliferative Disorder)
12/2021 - 01/2019
3Hematologic Neoplasms (Hematological Malignancy)
01/2021 - 09/2012
3White Coat Hypertension
03/2015 - 04/2007
3Ulcer
05/2014 - 10/2005
3Type 2 Diabetes Mellitus (MODY)
03/2013 - 04/2004
3Acute Coronary Syndrome
10/2012 - 01/2012
3Apnea
10/2012 - 09/2006
3Cardiac Sudden Death (Sudden Cardiac Arrest)
07/2012 - 03/2007
3Cognitive Dysfunction
06/2012 - 07/2008
3Insulin Resistance
04/2011 - 01/2007
3Fibrosis (Cirrhosis)
11/2008 - 03/2006
3Heart Diseases (Heart Disease)
04/2008 - 10/2002

Drug/Important Bio-Agent (IBA)

26Antihypertensive Agents (Antihypertensives)IBA
12/2022 - 01/2002
16Rituximab (Mabthera)FDA Link
12/2020 - 02/2004
12Aspirin (Acetylsalicylic Acid)FDA LinkGeneric
02/2020 - 06/2008
12Angiotensin Receptor AntagonistsIBA
01/2018 - 05/2003
12Pharmaceutical PreparationsIBA
02/2017 - 01/2005
11olmesartanIBA
10/2018 - 04/2011
10DiureticsIBA
10/2015 - 01/2002
10Losartan (Cozaar)FDA LinkGeneric
05/2015 - 04/2004
9Calcium Channel Blockers (Blockers, Calcium Channel)IBA
01/2020 - 05/2002
9Proteins (Proteins, Gene)FDA Link
12/2017 - 12/2004
9Angiotensin IIIBA
08/2012 - 10/2002
9C-Reactive ProteinIBA
11/2011 - 10/2002
8Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA
06/2012 - 03/2002
8LipidsIBA
01/2012 - 03/2002
7DNA (Deoxyribonucleic Acid)IBA
10/2021 - 08/2003
7Glucose (Dextrose)FDA LinkGeneric
02/2017 - 01/2007
7azelnidipineIBA
03/2013 - 06/2007
7CholesterolIBA
07/2008 - 07/2002
6LigandsIBA
12/2021 - 01/2004
6benidipineIBA
01/2020 - 08/2011
6Sodium Chloride Symporter Inhibitors (Diuretics, Thiazide)IBA
01/2018 - 04/2005
6Biomarkers (Surrogate Marker)IBA
05/2015 - 01/2007
6Amlodipine (Norvasc)FDA LinkGeneric
05/2015 - 05/2002
6Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
05/2012 - 03/2002
6Eicosapentaenoic AcidIBA
01/2012 - 07/2008
5Oxygen (Dioxygen)IBA
01/2021 - 08/2002
5Hydrochlorothiazide (Esidrix)FDA LinkGeneric
05/2015 - 04/2011
5Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA
11/2011 - 01/2002
41,4-dihydropyridine (dihydropyridine)IBA
01/2018 - 12/2009
4Histones (Histone)IBA
12/2017 - 12/2004
4Valsartan (Vals)FDA Link
01/2017 - 09/2004
4antineoplaston A10 (A 10)IBA
02/2014 - 12/2003
4CalciumIBA
11/2013 - 05/2002
4Doxazosin (Cardura)FDA LinkGeneric
01/2013 - 08/2004
4oxidized low density lipoproteinIBA
01/2012 - 04/2002
4Chemokine CCL2 (Monocyte Chemoattractant Protein 1)IBA
03/2006 - 04/2002
3Anti-Bacterial Agents (Antibiotics)IBA
01/2022 - 10/2003
3Methotrexate (Mexate)FDA LinkGeneric
12/2021 - 01/2019
3AntibodiesIBA
01/2021 - 01/2019
3Prednisolone (Predate)FDA LinkGeneric
12/2020 - 01/2015
3ThiazidesIBA
01/2020 - 04/2012
3CreatinineIBA
11/2018 - 08/2010
3N- acetyl- S- (alpha- methyl- 4- (2- methylpropyl)benzeneacetyl)cysteine 4-(nitrooxy)butyl esterIBA
04/2018 - 12/2014
3GhrelinIBA
05/2014 - 01/2010
3Hemostatics (Antihemorrhagics)IBA
04/2013 - 07/2005
3AlbuminsIBA
03/2013 - 06/2008
3Olmesartan Medoxomil (Votum)FDA Link
05/2012 - 12/2009
3Monoclonal AntibodiesIBA
04/2011 - 09/2009
3Insulin (Novolin)FDA Link
06/2010 - 06/2006
3AdiponectinIBA
06/2009 - 01/2007
3Adrenergic Agents (Adrenergic Drugs)IBA
06/2009 - 07/2002

Therapy/Procedure

42Therapeutics
10/2022 - 09/2002
13Drug Therapy (Chemotherapy)
09/2022 - 04/2008
3Aftercare (After-Treatment)
01/2019 - 05/2002
3Denervation
01/2019 - 01/2015
3Secondary Prevention
06/2011 - 03/2007